Crossmark

Unveiling the prognostic and therapeutic landscape of the zinc transporter protein SLC39A family in colorectal cancer through multi-omics and machine learning approaches

Crossref DOI link: https://doi.org/10.1007/s10238-025-01996-2

Published Online: 2026-03-21

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Chen, Haizhen

Chen, Chaozhao

Chen, Jie

Zheng, Huang

Zhu, Xinhao

Yu, Qianru

Zhou, Jiajie

Zong, Jiasheng

Lu, Tingyan

Sun, Jing

Shao, Yanfei

Zheng, Minhua
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (82273344)

National Natural Science Foundation of China (82072614)

College Students’ Innovative Entrepreneurial Training Plan Program (19250101)
License Information

Text and Data Mining valid from 2026-03-21

Version of Record valid from 2026-04-01
More Information

Article History

Received: 13 July 2025

Accepted: 2 December 2025

First Online: 21 March 2026

Declarations

:

: The authors declare no competing interests.

: This study was approved by the Ethics Committee of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine (Ethics Approval number: NCT04714814).

: All procedures involving human subjects were conducted in accordance with the Declaration of Helsinki, and written informed consent was obtained from all patients whose tissue samples were used.

: The authors affirm that human research participants provided informed consent for publication of the images in Fig. 10.”

Document is current

Any future updates will be listed below